07:00 , Oct 1, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $0.60 to $24.21 last week after completing submission of a rolling NDA to FDA seeking accelerated approval of ponatinib to treat resistant or intolerant chronic myelogenous leukemia (CML)...
01:00 , Sep 26, 2012 |  BC Extra  |  Financial News

Clinigen up in trading debut

Clinigen Group plc (LSE:CLIN) closed its first day of trading Tuesday on LSE's AIM at 176p, which is 12p above the share price in the company's IPO last week. Clinigen raised L10 million ($16.2 million)...
00:39 , Sep 20, 2012 |  BC Extra  |  Financial News

Clinigen raises L10 million in IPO

Clinigen Group Ltd. (Burton-on-Trent, U.K.) raised L10 million ($16.2 million) through the sale of 6.1 million shares at 164p in an IPO on LSE's AIM. The price values Clinigen at L135.4 million ($219.6 million). Selling...
07:00 , May 14, 2012 |  BC Week In Review  |  Company News

BL&H, Clinigen Group, Hospira, AstraZeneca sales and marketing update

Clinigen's Clinigen Healthcare division granted BL&H exclusive rights to commercialize Foscavir foscarnet in South Korea. The companies will collaborate on regulatory approval for the product to treat herpes, cytomegalovirus (CMV) infection and CMV in hematopoietic...